SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 10/9/2015 7:50:01 AM - Followers: 723 - Board type: Free - Posts Today: 3


(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+





Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
OCTOBER 08, 2015

Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
OCTOBER 06, 2015
Amarantus to Present at the 2015 Aegis Growth Conference
Oct. 05, 2015

Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
 OCTOBER 01, 2015
Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
OCTOBER 01, 2015
$AMBS OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies – October 1
Sept. 28, 2015
A leg up on multiple sclerosis (and Alzheimer’s)
September 2015
Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
SEPTEMBER 14, 2015

Amarantus Announces Results of Annual Meeting
SEPTEMBER 03, 2015
Amarantus Moves Annual Meeting Date Forward to September 2, 2015
AUGUST 26, 2015

Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
 AUGUST 20, 2015
Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
AUGUST 17, 2015
Amarantus Announces Adjournment of Annual Meeting
AUGUST 07, 2015
Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
AUGUST 05, 2015

 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015
 Predicting Alzheimer's before it      starts Published on Apr. 8, 2015
SNNLive - Amarantus BioScience
Holdings, Inc. - 
Dec. 12, 2014
Amarantus BioScience
Oct. 19, 2014
 Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014


Contact Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111


c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (415) 688-4484
Fax: (408) 852-4427

Gerald's email address

IR Calendar 



Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475



VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179


Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

                                         Watch the AMBS OTCQX Life Sciences Conference Presentation  -  Oct 1, 2015 


                                                                                       2015 Aegis Growth Conference
October 7-9, 2015 in Las Vegas, Nevada.- 
Gerald E. Commissiong, President & CEO of Amarantus, will present a corporate update on Friday, October 9, 2015 at 11:25 a.m. PDT. - A live webcast of the presentation may be accessed via the Amarantus IR Calendar located on the News and Events page of the Investor Relations section of the Company’s website ( The webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Current Report Filing (8-k) 10/08/2015 04:48:01 PM
AMBS News: Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of C... 10/08/2015 08:34:03 AM
AMBS News: Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease 10/06/2015 08:30:00 AM
AMBS News: Amarantus to Present at the 2015 Aegis Growth Conference 10/05/2015 10:48:32 AM
AMBS News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 10/01/2015 04:48:29 PM
News News Alert: Current Report Filing (8-k) 10/08/2015 04:48:01 PM
#117775  Sticky Note A leg up on multiple sclerosis (and Alzheimer’s) zoomboom 09/18/15 12:03:13 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#118371   100%' not a problem with the pipeline Alapis 10/09/15 07:50:01 AM
#118368   AMBS Business Plan 101 JPetroInc 10/08/15 10:48:27 PM
#118367   from $12 in May to $1 in Oct. JPetroInc 10/08/15 10:28:34 PM
#118366   The TPP deal with respect to biologics patent GS1 10/08/15 10:23:17 PM
#118365   Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company BBalls-N-CowTown 10/08/15 07:55:18 PM
#118363   Why is tomorrow D-Day? Slmiley 10/08/15 06:34:24 PM
#118362   I think we're down because fear rules the sante1 10/08/15 05:22:50 PM
#118361   Was there an official rejection to up list Ragnaroc 10/08/15 04:25:24 PM
#118360   "We are supremely confident in our Pipe" JPetroInc 10/08/15 03:58:34 PM
#118359   BELOW $1 TOMORROW GLTA. LORD of the TITANS 10/08/15 03:12:53 PM
#118357   That was nice bid support too:( GOducks123 10/08/15 10:06:40 AM
#118356   20k filled with NO move in the pps....dilution Alapis 10/08/15 10:04:53 AM
#118355   omg i see a 20k GC starting Alapis 10/08/15 10:01:55 AM
#118354   Precisely right - some are holding huge positions JPetroInc 10/08/15 09:57:00 AM
#118353   Beware! PRE RS was trading at .04 21ZNA9 10/08/15 09:43:07 AM
#118352   AMBS Down 97% YTD. Stay away from 21ZNA9 10/08/15 09:42:52 AM
#118351   Warning! 150-1 Reverse Split in play. Shares 21ZNA9 10/08/15 09:42:32 AM
#118350   first minutes show that GC is further diluting Alapis 10/08/15 09:35:52 AM
#118349   if the news on ESS are so good Alapis 10/08/15 09:34:01 AM
#118348   you have the GC virus red...i will stop Alapis 10/08/15 09:30:19 AM
#118347   That would explain your 20 posts a day. redspeed 10/08/15 09:29:08 AM
#118346   i did listen to it red...ESS is dead Alapis 10/08/15 09:27:03 AM
#118345   If you'd listen to the presentation. You would redspeed 10/08/15 09:25:05 AM
#118343   It's no mystery why they continue to dilute. hnbadger1 10/08/15 09:04:00 AM
#118342   it is RECYCLED NEWS's from a presentation Alapis 10/08/15 09:02:44 AM
#118341   Rosym give me a brake please..GC is a Alapis 10/08/15 09:01:40 AM
#118340   Listen to the call last week and read redspeed 10/08/15 09:00:10 AM
#118339   I agree with Christjamin. I wish you can Rosym 10/08/15 08:57:58 AM
#118338   hey you say that and you are still Alapis 10/08/15 08:49:21 AM
#118337   Hummmm.. If they start recycling news, they are christjamin 10/08/15 08:46:37 AM
#118336   sad but true....did you sell your shares? Alapis 10/08/15 08:43:00 AM
#118335   John is 70. He's tired. He was nodding JPetroInc 10/08/15 08:41:20 AM
#118334   the presentation was in May...why filing now? Alapis 10/08/15 08:24:07 AM
#118333   8k Sec filing. Crusade7 10/08/15 08:20:10 AM
#118332   not so sure why the show us the Alapis 10/08/15 07:44:02 AM
#118331   Gc's performance is a total mess...look how many Alapis 10/08/15 07:37:25 AM
#118330   whats to monitor JPetroInc 10/08/15 06:44:49 AM
#118329  Restored Aegis - great - more slimey scumbucket financing JPetroInc 10/08/15 06:16:09 AM
#118328   a drink is not enough after all the Alapis 10/08/15 12:36:40 AM
#118327   He'll be hiding at the Aegis Growth Conference redspeed 10/07/15 09:42:59 PM
#118326   Gerald is hiding himself. He knows damned wel sante1 10/07/15 09:26:19 PM
#118325   Use of Tissue Engineered Skin Substitutes Accelerates as redspeed 10/07/15 07:55:39 PM
#118324   Daily TA Chart JPetroInc 10/07/15 06:50:06 PM
#118323   Daily dilution count JPetroInc 10/07/15 06:44:07 PM
#118322   Johns working in the back Janssen lab right JPetroInc 10/07/15 06:35:40 PM
#118321   what the hell are these guys doing? JPetroInc 10/07/15 04:21:15 PM
#118320   ESS in the right set of hands - JPetroInc 10/07/15 04:06:48 PM
#118319   thought they were working on CD-69 testing for JPetroInc 10/07/15 02:08:35 PM
#118318   at the time of the "partnership" AVXL was Alapis 10/07/15 12:52:08 PM
#118317   unfortunately they are NOT our partner Alapis 10/07/15 12:50:03 PM